In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes

Tsang Pai Liu, Yi Han Hong, Kwang Yi Tung, Pei Ming Yang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

There are currently no effective molecular targeted therapies for hepatocellular carcinoma (HCC), the third leading cause of cancer-related death worldwide. Enhancer of zeste homolog 2 (EZH2), a histone H3 lysine 27 (H3K27)-specific methyltransferase, has been emerged as novel anticancer target. Our previous study has demonstrated that GSK343, an S-adenosyl-L-methionine (SAM)-competitive inhibitor of EZH2, induces autophagy and enhances drug sensitivity in cancer cells including HCC. In this study, an in silico study was performed and found that EZH2 was overexpressed in cancerous tissues of HCC patients at both gene and protein levels. Microarray analysis and in vitro experiments indicated that the anti-HCC activity of GSK343 was associated with the induction of metallothionein (MT) genes. In addition, the negative association of EZH2 and MT1/MT2A genes in cancer cell lines and tissues was found in public gene expression database. Taken together, our findings suggest that EZH2 inhibitors could be a good therapeutic option for HCC, and induction of MT genes was associated with the anti-HCC activity of EZH2 inhibitors.

Original languageEnglish
Pages (from-to)9-20
Number of pages12
JournalOncoscience
Volume3
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Metallothionein
Computer Simulation
Hepatocellular Carcinoma
Genes
Therapeutics
Molecular Targeted Therapy
S-Adenosylmethionine
Neoplasm Genes
Autophagy
Methyltransferases
Microarray Analysis
Histones
Lysine
Enhancer of Zeste Homolog 2 Protein
GSK343
Neoplasms
Databases
Gene Expression
Cell Line
Pharmaceutical Preparations

Keywords

  • EZH2
  • Hepatocellular carcinoma
  • Metallothionein
  • Microarray analysis
  • Therapeutic biomarker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes. / Liu, Tsang Pai; Hong, Yi Han; Tung, Kwang Yi; Yang, Pei Ming.

In: Oncoscience, Vol. 3, No. 1, 2016, p. 9-20.

Research output: Contribution to journalArticle

@article{964058c1088a42c582652c5b038d2d41,
title = "In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes",
abstract = "There are currently no effective molecular targeted therapies for hepatocellular carcinoma (HCC), the third leading cause of cancer-related death worldwide. Enhancer of zeste homolog 2 (EZH2), a histone H3 lysine 27 (H3K27)-specific methyltransferase, has been emerged as novel anticancer target. Our previous study has demonstrated that GSK343, an S-adenosyl-L-methionine (SAM)-competitive inhibitor of EZH2, induces autophagy and enhances drug sensitivity in cancer cells including HCC. In this study, an in silico study was performed and found that EZH2 was overexpressed in cancerous tissues of HCC patients at both gene and protein levels. Microarray analysis and in vitro experiments indicated that the anti-HCC activity of GSK343 was associated with the induction of metallothionein (MT) genes. In addition, the negative association of EZH2 and MT1/MT2A genes in cancer cell lines and tissues was found in public gene expression database. Taken together, our findings suggest that EZH2 inhibitors could be a good therapeutic option for HCC, and induction of MT genes was associated with the anti-HCC activity of EZH2 inhibitors.",
keywords = "EZH2, Hepatocellular carcinoma, Metallothionein, Microarray analysis, Therapeutic biomarker",
author = "Liu, {Tsang Pai} and Hong, {Yi Han} and Tung, {Kwang Yi} and Yang, {Pei Ming}",
year = "2016",
doi = "10.18632/oncoscience.285",
language = "English",
volume = "3",
pages = "9--20",
journal = "Oncoscience",
issn = "2331-4737",
publisher = "Impact Journals",
number = "1",

}

TY - JOUR

T1 - In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes

AU - Liu, Tsang Pai

AU - Hong, Yi Han

AU - Tung, Kwang Yi

AU - Yang, Pei Ming

PY - 2016

Y1 - 2016

N2 - There are currently no effective molecular targeted therapies for hepatocellular carcinoma (HCC), the third leading cause of cancer-related death worldwide. Enhancer of zeste homolog 2 (EZH2), a histone H3 lysine 27 (H3K27)-specific methyltransferase, has been emerged as novel anticancer target. Our previous study has demonstrated that GSK343, an S-adenosyl-L-methionine (SAM)-competitive inhibitor of EZH2, induces autophagy and enhances drug sensitivity in cancer cells including HCC. In this study, an in silico study was performed and found that EZH2 was overexpressed in cancerous tissues of HCC patients at both gene and protein levels. Microarray analysis and in vitro experiments indicated that the anti-HCC activity of GSK343 was associated with the induction of metallothionein (MT) genes. In addition, the negative association of EZH2 and MT1/MT2A genes in cancer cell lines and tissues was found in public gene expression database. Taken together, our findings suggest that EZH2 inhibitors could be a good therapeutic option for HCC, and induction of MT genes was associated with the anti-HCC activity of EZH2 inhibitors.

AB - There are currently no effective molecular targeted therapies for hepatocellular carcinoma (HCC), the third leading cause of cancer-related death worldwide. Enhancer of zeste homolog 2 (EZH2), a histone H3 lysine 27 (H3K27)-specific methyltransferase, has been emerged as novel anticancer target. Our previous study has demonstrated that GSK343, an S-adenosyl-L-methionine (SAM)-competitive inhibitor of EZH2, induces autophagy and enhances drug sensitivity in cancer cells including HCC. In this study, an in silico study was performed and found that EZH2 was overexpressed in cancerous tissues of HCC patients at both gene and protein levels. Microarray analysis and in vitro experiments indicated that the anti-HCC activity of GSK343 was associated with the induction of metallothionein (MT) genes. In addition, the negative association of EZH2 and MT1/MT2A genes in cancer cell lines and tissues was found in public gene expression database. Taken together, our findings suggest that EZH2 inhibitors could be a good therapeutic option for HCC, and induction of MT genes was associated with the anti-HCC activity of EZH2 inhibitors.

KW - EZH2

KW - Hepatocellular carcinoma

KW - Metallothionein

KW - Microarray analysis

KW - Therapeutic biomarker

UR - http://www.scopus.com/inward/record.url?scp=84958743826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958743826&partnerID=8YFLogxK

U2 - 10.18632/oncoscience.285

DO - 10.18632/oncoscience.285

M3 - Article

AN - SCOPUS:84958743826

VL - 3

SP - 9

EP - 20

JO - Oncoscience

JF - Oncoscience

SN - 2331-4737

IS - 1

ER -